Evidence map›Paper›PMID 39539943›Full record

ArticleTherapeutic advances in medical oncology2024

Elacestrant plus alpelisib in an

Ünal Metin Tokat, Şevval Nur Bilgiç, Esranur Aydın, Ashkan Adibi, Eylül Özgü, Onur Tutar, Mutlu Demiray

Abstract readCase Reports
In one paragraph

Article in Therapeutic advances in medical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology.Virchows Archiv : an international journal of pathology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ünal Metin TokatPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.ORCID https://orcid.org/0000-0003-0026-368X
Şevval Nur BilgiçPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.ORCID https://orcid.org/0000-0002-9574-1471
Esranur AydınPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.ORCID https://orcid.org/0000-0001-7850-0177
Ashkan AdibiPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Eylül ÖzgüPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.ORCID https://orcid.org/0000-0002-6264-1546
Onur TutarDepartment of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Mutlu DemirayPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.ORCID https://orcid.org/0000-0003-2501-3097

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up the majority of all cases. The standard of care in HR

Indexed as

alpelisibcancer genomicscase reportelacestrantESR1/PIK3CA co-mutationsHR-positive/HER2-negative metastatic breast cancerselective estrogen receptor degrader (SERD)

Identifiers

PMID39539943
PMCPMC11558728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.